Eris Lifesciences Ltd

ERIS Lifesciences Ltd share price softened by 2.14% to Rs 1097.65. The Company's net profit surged by 30.57% to Rs 187.14 crore, while revenue from operations slightly gained 2.36% to Rs 889.5 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.19 lakh crore, easing 3.50%. It has eased by 1.73% over last one week and softened by 3.54% in last one month while the market capitalization of ERIS Lifesciences Ltd has slipped by 2.49% and 21.02% in the same period respectively. Profit before tax (PBT) of ERIS Lifesciences Ltd stood at Rs 155.91 crore in Q3 FY26, declining 9.71% year-on-year, and retreating 13.14% quarter-on-quarter. EBITDA came in at Rs 306 crore, rising 7.27% YoY and gaining 4.19% sequentially. Total expenses inched up 1.13% to Rs 656.44 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 107.86 crore, increasing 14.42% YoY, while employee benefits expense was at Rs 149.19 crore, softening 2.76% YoY. For the TTM ended FY26, revenue from operations posted a slight growth of 8.18% to Rs 3114.89 crore, while net profit soared by 72.82% to Rs 647.51 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 96188% to Rs 1112.36 crore, and PBT soared 30.62% to Rs 638.54 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 537.99 crore in FY26, as against Rs 1065.01 crore in FY25. ERIS Lifesciences Ltd crashed 30.95% in last one year, underperforming the benchmark BSE Sensex which has reduced by 13.52% during the same period.

Eris Lifesciences Limited will hold a board meeting on Monday, October 26, 2026, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2026, the company said in a filing. The trading window for the company has been closed from October 1, 2026, and will remain closed until 48 hours after the financial results are declared, in accordance with SEBI regulations.

Eris Lifesciences Limited submitted a certificate to the Bombay Stock Exchange and National Stock Exchange under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, its Registrar and Share Transfer Agent.

Eris Lifesciences Limited will close its trading window for designated persons and their immediate relatives from October 1, 2026, until 48 hours after the public declaration of the company’s unaudited financial results for the quarter and half year ending September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Eris Lifesciences Limited announced the allotment of 1,55,264 equity shares on September 22, 2026, following the exercise of options under the ESOP-2021 Scheme, with 66,422 shares issued at Rs 557.24, 57,239 shares at Rs 510.32, and 31,603 shares at Rs 728.16, increasing the company's paid-up share capital from Rs 13,85,83,305 to Rs 13,87,38,569.

Eris Lifesciences Limited announced that Krishnakumar Vaidyanathan has resigned from his position as Executive Director & Chief Operating Officer (COO), effective September 30, 2026, to pursue professional opportunities outside the organization.

Eris Lifesciences Limited informed the Bombay Stock Exchange and National Stock Exchange of India that its board of directors approved the re-appointment of Mr. Sujesh Vasudevan as an Independent Director for a period of 5 years, commencing July 25, 2027, and up to July 24, 2032, and convened the 20th Annual General Meeting of its members for September 25, 2026.

Eris Lifesciences Limited announced on July 30, 2026, the allotment of 4,816 equity shares at a premium of Rs 450.04 per share, pursuant to the exercise of options under the ESOP-2017 Scheme, increasing the company's paid-up share capital from Rs 13,85,78,489 to Rs 13,85,83,305.

Revenue from operations grew 12.97% YoY to Rs 873.25 crore during the quarter. Profit before tax (PBT) jumped 11.42% YoY to Rs 179.49 crore in Q1 FY27. EBITDA rose 7.1% YoY to Rs 296 crore from Rs 277 crore in the year-ago quarter. However, EBITDA margin contracted to 33.9% in Q1 FY27 from 35.8% in Q1 FY26. During the quarter, revenue from domestic branded formulations (DBF) segment stood at Rs 801 crore, up 14% YoY Meanwhile, revenue from the international business increased 5% YoY to Rs 72 crore during the quarter. Eris Lifesciences is an Indian pharmaceutical company and a leading player in the domestic branded formulations market. The company is engaged in the manufacturing and marketing of pharmaceutical products.Powered by Capital Market - Live

Net profit of ERIS Lifesciences rose 20.68% to Rs 142.39 crore in the quarter ended June 2026 as against Rs 117.99 crore during the previous quarter ended June 2025. Sales rose 12.63% to Rs 869.03 crore in the quarter ended June 2026 as against Rs 771.56 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales869.03771.56 13 OPM %34.0435.86 - PBDT251.56231.61 9 PBT179.49161.10 11 NP142.39117.99 21 Powered by Capital Market - Live